EP4659740A2 — Kx2-391/kx-01 for use in the treatment of actinic keratosis
Assigned to Atnx Spv LLC Canada · Expires 2025-12-10 · 0y expired
What this patent protects
A compound for use in a method of treating and/or preventing actinic keratosis in a subject in need thereof, the method comprising topically administering the compound to an affected area of the subject once a day at a dose of from 0.5 mg to 4 mg, wherein the affected area is 0.1…
USPTO Abstract
A compound for use in a method of treating and/or preventing actinic keratosis in a subject in need thereof, the method comprising topically administering the compound to an affected area of the subject once a day at a dose of from 0.5 mg to 4 mg, wherein the affected area is 0.1 cm 2 to 100 cm 2 , and wherein the compound is KX-01:
Drugs covered by this patent
- Klisyri (TIRBANIBULIN) · Almirall
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.